Europe Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Europe Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030


The Europe Retinal Biologics Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).

In both real-world situations and clinical trials, retinal biologics have been shown to produce better therapeutic results than conventional therapies. Patients and healthcare professionals find these therapies very appealing since they offer the potential to slow the advancement of the disease, enhance eyesight, and even reverse some of the consequences of retinal diseases. Typically, biological organisms like microbes, animal or plant cells, or other living entities are used to generate biologics. Retinal biologics are a novel class of drugs that work by aiming at particular indicators in the body of the patient to reduce the symptoms of various systemic or ocular conditions that manifest as eye problems.

Advances in biotechnology and an increase in the elderly population with retinal disorders are driving the market's expansion. Furthermore, retinal illnesses are more common among the elderly. Therefore, the aging population has raised the need for retinal biologic medicines and spurred market expansion.

According to estimates of European Blind Union (EBU), there are 30 million blind and partially sighted people living in Europe. On average, one in thirty Europeans experience vision loss, and the number of partially sighted people outnumbers the number of blind people by a factor of four. Women are more likely than men to go blind or partially blind. One in three seniors over the age of 65 has a visual loss, according to the EBU. 90% of those who are blind or visually impaired are older than 65. This greater estimate explains why it is challenging to determine with precision the prevalence of sight loss among Europe's aging population. Additionally, there are many people with various degrees of sight loss who choose not to report their illness due to ignorance or other personal factors. Consequently, such factors aid in the expansion of the market in the coming years.

The Germany market dominated the Europe Retinal Biologics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,153.2 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.5% during (2023 - 2030).

Based on Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Drug Class, the market is segmented into VEGF-A Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.

Scope of the Study

Market Segments covered in the Report:

By Indication
  • Macular Degeneration
  • Diabetic Retinopathy
  • Others
By Drug Class
  • VEGF-A Antagonist
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Novartis AG
  • Amgen, Inc.
  • AbbVie, Inc.
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health Companies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • MeiraGTx Holdings plc
  • Oxurion NV
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Retinal Biologics Market, by Indication
1.4.2 Europe Retinal Biologics Market, by Drug Class
1.4.3 Europe Retinal Biologics Market, by Distribution Channel
1.4.4 Europe Retinal Biologics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. Europe Retinal Biologics Market by Indication
5.1 Europe Macular Degeneration Market by Country
5.2 Europe Diabetic Retinopathy Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Retinal Biologics Market by Drug Class
6.1 Europe VEGF-A Antagonist Market by Country
6.2 Europe Others Market by Country
Chapter 7. Europe Retinal Biologics Market by Distribution Channel
7.1 Europe Hospital Pharmacy Market by Country
7.2 Europe Retail Pharmacy Market by Country
7.3 Europe Online Pharmacy Market by Country
Chapter 8. Europe Retinal Biologics Market by Country
8.1 Germany Retinal Biologics Market
8.1.1 Germany Retinal Biologics Market by Indication
8.1.2 Germany Retinal Biologics Market by Drug Class
8.1.3 Germany Retinal Biologics Market by Distribution Channel
8.2 UK Retinal Biologics Market
8.2.1 UK Retinal Biologics Market by Indication
8.2.2 UK Retinal Biologics Market by Drug Class
8.2.3 UK Retinal Biologics Market by Distribution Channel
8.3 France Retinal Biologics Market
8.3.1 France Retinal Biologics Market by Indication
8.3.2 France Retinal Biologics Market by Drug Class
8.3.3 France Retinal Biologics Market by Distribution Channel
8.4 Russia Retinal Biologics Market
8.4.1 Russia Retinal Biologics Market by Indication
8.4.2 Russia Retinal Biologics Market by Drug Class
8.4.3 Russia Retinal Biologics Market by Distribution Channel
8.5 Spain Retinal Biologics Market
8.5.1 Spain Retinal Biologics Market by Indication
8.5.2 Spain Retinal Biologics Market by Drug Class
8.5.3 Spain Retinal Biologics Market by Distribution Channel
8.6 Italy Retinal Biologics Market
8.6.1 Italy Retinal Biologics Market by Indication
8.6.2 Italy Retinal Biologics Market by Drug Class
8.6.3 Italy Retinal Biologics Market by Distribution Channel
8.7 Rest of Europe Retinal Biologics Market
8.7.1 Rest of Europe Retinal Biologics Market by Indication
8.7.2 Rest of Europe Retinal Biologics Market by Drug Class
8.7.3 Rest of Europe Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Novartis AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Amgen, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Approvals & Trials:
9.3.6 SWOT Analysis
9.4 Bayer AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Approvals & Trials:
9.7.5.3 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Approvals & Trials:
9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 SWOT Analysis
9.10. Oxurion NV
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses
9.10.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings